Factors associated with efficacy of FOLFIRI/aflibercept in patients with metastatic colon cancer

M. Yu. Fedyanin; Федянин М. Ю.; L. Yu. Vladimirova; Владимирова Л. Ю.; V. A. Chubenko; Чубенко В. А.; L. A. Zagorskaya; Загорская Л. А.; A. V. Belyaeva; Беляева А. В.; L. V. Bolotina; Болотина Л. В.; F. V. Moiseenko; Моисеенко Ф. В.; O. L. Fakhrutdinova; Фахрутдинова О. Л.; S. A. Belukhin; Белухин С. А.; A. S. Zhabina; Жабина А. С.; L. V. Khalikova; Халикова Л. В.; V. M. Moiseenko; Моисеенко В. М.; А. А. Meshcheryakov; Мещеряков А. А.; E. V. Artamonova; Артамонова Е. В.; I. A. Pokataev; Покатаев И. А.; A. I. Khasanova; Хасанова А. И.; A. V. Belonogov; Белоногов А. В.; Kh. S. Musaeva; Мусаева Х. С.; O. Yu. Novikova; Новикова О. Ю.; I. Yu. Stradaeva; Страдаева И. Ю.; I. L. Popova; Попова И. Л.; G. Z. Mukhametshina; Мухаметшина Г. З.; R. V. Orlova; Орлова Р. В.; S. P. Erdniev; Эрдниев С. П.; A. K. Ivanova; Иванова А. К.; A. V. Androsova; Андросова А. В.; P. S. Feoktistova; Феоктистова П. С.; E. S. Kuzmina; Кузьмина Е. С.; E. V. Karabina; Карабина Е. В.; O. V. Nekrasova; Некрасова О. В.; V. M. Sherstnev; Шерстнев В. М.; A. A. Mishchenko; Мищенко А. А.; L. A. Mukova; Мукова Л. А.; B. Kh. Kertiev; Кертиев Б. Х.; G. I. Kosar; Косарь Г. И.; S. N. Osodoeva; Осодоева С. Н.; A. I. Kats; Кац А. И.; R. R. Malina; Малина Р. Р.; A. A. Tryakin; Трякин А. А.; S. A. Tjulandin; Тюляндин С. А.

doi:10.17650/2220-3478-2019-9-2-29-37

Factors associated with efficacy of FOLFIRI/aflibercept in patients with metastatic colon cancer

Authors: Fedyanin M.Y.¹, Vladimirova L.Y.², Chubenko V.A.³, Zagorskaya L.A.³, Belyaeva A.V.³, Bolotina L.V.⁴, Moiseenko F.V.³, Fakhrutdinova O.L.³, Belukhin S.A.³, Zhabina A.S.³, Khalikova L.V.³, Moiseenko V.M.³, Meshcheryakov А.А.¹, Artamonova E.V.¹, Pokataev I.A.¹, Khasanova A.I.⁵, Belonogov A.V.⁶, Musaeva K.S.⁷, Novikova O.Y.⁸, Stradaeva I.Y.⁹, Popova I.L.², Mukhametshina G.Z.⁵, Orlova R.V.¹⁰, Erdniev S.P.¹¹, Ivanova A.K.¹¹, Androsova A.V.¹¹, Feoktistova P.S.¹², Kuzmina E.S.¹³, Karabina E.V.¹⁴, Nekrasova O.V.¹⁵, Sherstnev V.M.¹⁶, Mishchenko A.A.¹⁷, Mukova L.A.¹⁸, Kertiev B.K.¹⁸, Kosar G.I.¹⁹, Osodoeva S.N.²⁰, Kats A.I.²¹, Malina R.R.²¹, Tryakin A.A.¹, Tjulandin S.A.¹
Affiliations:
1. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2. Rostov Research Institute of Oncology, Ministry of Health of Russia
3. Saint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of Russia
4. P.A. Hertzen Moscow Oncology Research Institute — branch of the National Medical Research Radiology Center, Ministry of Health of Russia
5. Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Tatarstan
6. MEDSIClinic
7. Republican Oncology Dispensary
8. Regional Clinical Center of Oncology
9. Moscow Regional Oncology Dispensary
10. Saint Petersburg State University
11. City Clinical Oncology Dispensary
12. Nizhnevartovsk Oncology Dispensary
13. Salekhard Regional Clinical Hospital
14. Tula Regional Oncology Dispensary
15. Multicare Medical Center “Medical City”
16. Oncology Dispensary No. 5, Moscow Healthcare Department
17. Primorsky Regional Oncology Dispensary
18. Oncology Dispensary, Ministry of Health of Kabardino-Balkar Republic
19. Volgodonsk Oncology Dispensary
20. Buryat Republican Oncology Dispensary
21. Oncology Dispensary
Issue: Vol 9, No 2 (2019)
Pages: 29-37
Section: ORIGINAL REPORT
Published: 16.06.2019
URL: https://onco-surgery.info/jour/article/view/289
DOI: https://doi.org/10.17650/2220-3478-2019-9-2-29-37
ID: 289

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Objective: to identify factors associated with efficacy of an aflibercept-chemotherapy combination in patients with metastatic colon cancer.

Materials and methods. This retrospective multicenter study was conducted in 20 clinics from 15 regions of the Russian Federation. The main efficacy outcome was progression-free survival (PFS). We performed univariate and multivariate analysis to assess the impact of various factors of PFS.

Results. Two hundred and fifty-seven patients received aflibercept-containing chemotherapy; of them, 175 participants (68.1 %) received it as a second-line therapy. The objective response rate and median PFS were 18.7% and 5 months (95% confidence interval (CI) 4.2—5.8) respec -tively. The following factors were found to have a positive effect of PFS at multivariate analysis: grade I—II adverse events to aflibercept therapy (hazard ratio (HR) 0.58; 95 % CI 0.38—0.89; p = 0.01), therapy for concomitant diseases (HR 0.47; 95 % CI 0.29—0.76; p = 0.002), and ECOG performance status of 0 (HR 0.53; 95 % CI 0.34—0.81; p = 0.004). Patient with all 3 factors present had median PFS of 9 months, whereas patients without them demonstrated PFS of only 3 months (HR 1.9; 95 % CI 1.5—2.6; p <0.001).

Conclusions. Satisfactory performance status, adequate therapy for concomitant diseases, and adverse events to aflibercept therapy were associated with better PFS in patients receiving aflibercept-containing chemotherapy.

Keywords

colon cancer, chemotherapy, aflibercept, population-based study, prognostic factors

About the authors

M. Yu. Fedyanin

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Author for correspondence.
Email: fedianinmu@mail.ru
ORCID iD: 0000-0001-5615-7806

24 Kashirskoe Shosse, Moscow 115478

Russian Federation

L. Yu. Vladimirova

Rostov Research Institute of Oncology, Ministry of Health of Russia

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

Factors associated with efficacy of FOLFIRI/aflibercept in patients with metastatic colon cancer

Full Text

Abstract

Keywords

About the authors

References

Supplementary files